The announcement was made after market hours on Thursday, 13 March 2014.

Meanwhile, the S&P BSE Sensex was down 142.24 points or 0.65% at 21,632.37

On BSE, so far 38,611 shares were traded in the counter as against average daily volume of 19,990 shares in the past one quarter.

The stock hit a high of Rs 1,169.80 and a low of Rs 1,124.90 so far during the day. The stock had hit a 52-week high of Rs 1,285 on 4 March 2014. The stock had hit a 52-week low of Rs 595 on 26 March 2013.

The stock had outperformed the market over the past one month till 13 March 2014, rising 31.76% compared with the Sensex's 7.83% rise. The scrip had also outperformed the market in past one quarter, gaining 31.67% as against Sensex's 5.11% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India said that the voluntary delisting proposal from AstraZeneca Pharmaceuticals AB, Sweden (AZP AB) will be considered at the meeting of the Board of Directors of the company to be held on 15 March 2014.

On 5 March 2014, Astrazeneca Pharma India said its board deferred the proposed delisting of the firm's shares from the domestic stock exchanges. AstraZeneca Pharma India, the Indian arm of Swedish drug maker AstraZeneca Pharmaceuticals AB (AZP AB), has deferred its delisting from the stock exchanges, which had been proposed by its parent company. The company's board, at a meeting on 5 March 2014, decided to seek additional information on the delisting proposal from the parent. Pending receipt of such additional information, consideration of the promoter's letter dated 1 March 2014 was deferred, the Indian company said in a statement.

On 1 March 2014, Astrazeneca Pharma India said that its board received a letter from AZP AB, promoter of the company, proposing to delist the equity shares of the company from Indian stock exchanges (BSE, NSE and Bangalore Stock Exchange). AZP AB holds 75% in the company (as per shareholding pattern as on 31 December 2013).

Astrazeneca Pharma India reported a net profit of Rs 1.52 crore in Q3 December 2013 as against net loss of Rs 17.70 crore in Q3 December 2012. Net sales rose 13.3% to Rs 118.88 crore in Q3 December 2013 over Q3 December 2012.

AstraZeneca Pharma India is one of the leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.